* If you want to update the article please login/register
"However, acute ischemic stroke patients with low NIHSS who harbor a large vessel occlusion suffer in 20-40% of cases and/or have underappreciated impairments due to their relatively mild strokes. " In the LVO mild stroke target population, the risk of immediate mechanical thrombectomy is limited. Patients with cerebral ischemia in the context of immediate large vessel occlusions and low baseline NIHSS scores will have improved 90-day clinical outcomes with prompt mechanical thrombectomy within 8 hours of diagnosis, according to this review.
Source link: https://clinicaltrials.gov/ct2/show/NCT04167527
Patients in Stroke with neurodegenerative Delay MIND are among the beneficiaries of a 3-year intervention into MIND, a Mediterranean and DASH diet that is intended to measure the effects of a three-year intervention by a Mediterranean and DASH diet that is developed for acute stroke patients who are hospitalized for acute stroke who are hospitalized for acute stroke and discharged home following hospitalization. The MIND diet has the same basic components of the DASH and Mediterranean diets, including emphasis on natural plant-based foods and limited animal and high saturated fat foods, but it is specifically designed for green leafy vegetable and berries as well as food component servings that represent the nutritional dementia findings. In 300 trial participants randomly chosen participants, biological consequences of the MIND diet will be determined by testing of brain macro and microstructural consistency.
Source link: https://clinicaltrials.gov/ct2/show/NCT04337255
"Use of dry electrode EEG caps will allow relatively new paramedics to perform a reliable test without having to wait for EEG preparation time associated with 'wet' EEGs. " We predict the time of EEG recording and analysis to be below five minutes, which would make stroke triage in the ambulance more efficient if EEG logistically feasible. This diagnostic research is divided into four phases: Phase 1: The improvement of measurement time and software settings of the dry electrode cap EEG in a non-emergency setting in patients in whom a routine EEG will be administered for standard medical care is/will be done. Phase 2: Optimizing measurement time and software settings of the dry electrode cap EEG in patients close to our target population in a non-emergency setting. Phase 4: Validation of several existing algorithms and algorithms developed in phase 3 for LVO-a detection in patients with a suspected AIS in the ambulance, as well as assessment of the medical and logistical feasibility of performing EEG with dry electrode caps in patients with suspected AIS in the ambulance. Patients with an AIS were admitted to the Neurology ward of the coordinating hospital with an LVO-a. Primary endpoint: LVO-a stroke in the prehospital setting was distinguished by the receiver operating characteristics curve of the receiver's equation, with the area under the receiver operating characteristics curve of the theta/alpha ratio.
Source link: https://clinicaltrials.gov/ct2/show/NCT03699397
"However, clinical trials aimed at neutrophil recruitment in AIS patients were non-operative. " Inhibition of neutrophil recruitment just a few hours after the outbreak of ischemia, it seems that it is therefore too late to have a medical relevance. In each time point, the goal is to determine the correct therapeutic target and time window.
Source link: https://clinicaltrials.gov/ct2/show/NCT02900833
"Fifty patients who have experienced a stroke onset within seven days will be recruited from the emergency room. " Both the measurement scales' results and the behavioral record of the fNIRS motor tasks will be collected as well. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05376098
"Long-term oral anticoagulation therapy is the most effective technique for secondary stroke prevention in patients with atrial fibrillation. " The question of optimal timing of NOAC initiation is becoming more important now that NOACs have become the mainstay of stroke prophylaxis in AFib, with more rapid and consistent anticoagulation and fewer strokes. With NOACs for acute stroke patients with non-valvular AFib, the primary aim is to determine the time-to-treatment interval with the lowest risk of adverse events in the context of anticoagulation therapy. Modeled separately using their well-known monotonic property, the possibility of an event rises or decreases as the time-to-treatment interval lengthens. Every 100 patients will be randomly selected, where the primary outcome will be analyzed, and new randomization rates will be established to favor the arms with a higher risk profile.
Source link: https://clinicaltrials.gov/ct2/show/NCT03021928
"Hypothesis In patients with ischemic stroke and small vessel disease, Remote Ischemic Conditioning provided by a novel device with an optical feedback sensor will be safe and effective. " If there is a occurrence of white-matter hyperintensities, the risk of worse outcomes in patients with ischemic stroke is increased by a odds ratio of 1. 96. To minimize the effect of WMH on stroke outcomes, the current care standard depends on prevention of cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, smoking, physical fitness, and mental health issues. So far in experimental stroke RIC alone or in combination with revascularization therapy, it has been promising to have additive action, improve collateral circulation, and reduced the infarct size. Improved cerebral blood flow, prevented white matter decay, improved angiogenesis, and cognitive outcomes were reported in animal models for cognitive impairment and dementia RIC for 1 month. WMH reduction in a year of a pilot human study RICs led to a decrease in WMH. The current recommended treatment for ischemia in the limb muscles is to raise the blood pressure in the leg 30-50 mmHg above the normal blood pressure to a maximum of 200 mmHg. Pressure in the upper limb can cause pain and reduced compliance, which can lead to decreased compliance. A more cost-effective option would be to establish the ideal pressure target for each individual.
Source link: https://clinicaltrials.gov/ct2/show/NCT05408130
"Patients with acute ischemic stroke and who are eligible for standard intravenous thrombolytic therapy within 4. 5 hours of stroke onset will be tested for major vessel occlusion to determine their eligibility for trial," says spokesperson "Dr. "Patients arriving in the emergency department with acute ischemic stroke and are eligible for standard intravenous thrombolytic therapy within 4. 5 hours of stroke onset will be assessed for compulsory thrombolytic therapy within 4. 5 hours of trial will be tested for major vessel occlusion will be assessed for critical hemoglobal thrombolytic therapy within thrombolytic therapy within occlusion for major vessel occlusion will be tested for the trial eligibility for the trial participation. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05203224
"Ischemic stroke is one of the illnesses that seriously threaten human health," the disease has high incidence, high mortality, and a high recurrence rate. " Butylphthalide can cause the destruction of the central nervous system in patients with acute ischemic stroke, as well as promote the growth of patients with neurological deficits. Although big data study based on real-world safety and security is lacking, there is still a lack of evidence on elderly patients' pharmacokinetics and their correlation with adverse reactions. So, 300 patients will be registered and treated intravenous butylphthalide sodium chloride injection 25mg twice a day for 7-14 days, and then oral butylphthalide soft capsule 0. 2g three times a day for 76-83 days. For 50 of them, a population pharmacokinetic model of butylphthalide in elderly patients was developed. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05068349
"The Find AF 2 report will determine whether enhanced rhythm monitoring in patients with recent ischemic stroke results in a decrease in thromboembolism in patients. " Patients with paroxysmal atrial fibrillation will be identified by paroxysmal atrial fibrillation, and then switched secondary prevention therapy from antiplatelet therapy to oral anticoagulation will be achieved. A 7-day Holter ECG is repeated after 3 and 12 months and annually thereafter, with an estimated low risk of atrial fibrillation. Patients at a high risk of atrial fibrillation are kept ECG monitored by an implanted loop recorder. A 24-hour Holter ECG is carried out in both study arms, assuring minimal ECG monitoring for patients in the control arm and allowing risk stratification in the intervention arm. Patients in both study arms will be followed for at least 24 months.
Source link: https://clinicaltrials.gov/ct2/show/NCT04371055
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions